학술논문
Small Intestinal Permeability and Metabolomic Profiles in Feces and Plasma Associate With Clinical Response in Patients With Active Psoriatic Arthritis Participating in a Fecal Microbiota Transplantation Trial: Exploratory Findings From the FLORA Trial
Document Type
Academic Journal
Author
Kragsnaes, Maja Skov; Blanco, Jesus Miguens; Mullish, Benjamin H.; Serrano‐Contreras, Jose Ivan; Kjeldsen, Jens; Horn, Hans Christian; Pedersen, Jens Kristian; Munk, Heidi Lausten; Nilsson, Anna Christine; Salam, Ash; Lewis, Matthew R.; Chekmeneva, Elena; Kristiansen, Karsten; Marchesi, Julian R.; Ellingsen, Torkell
Source
ACR Open Rheumatology. November, 2023, Vol. 5 Issue 11, p583, 11 p.
Subject
Language
English
Abstract
Objective: We investigated intestinal permeability and fecal, plasma, and urine metabolomic profiles in methotrexate‐treated active psoriatic arthritis (PsA) and how this related to clinical response following one sham or fecal microbiota transplantation (FMT). Methods: This exploratory study is based on the FLORA trial cohort, in which 31 patients with moderate‐to‐high peripheral PsA disease activity, despite at least 3 months of methotrexate‐treatment, were included in a 26‐week, double‐blind, 1:1 randomized, sham‐controlled trial. Participants were randomly allocated to receive either one healthy donor FMT (n = 15) or sham (n = 16) via gastroscopy. The primary trial end point was the proportion of treatment failures through 26 weeks. We performed a lactulose‐to‐mannitol ratio (LMR) test at baseline (n = 31) and at week 26 (n = 26) to assess small intestinal permeability. Metabolomic profiles in fecal, plasma, and urine samples collected at baseline, weeks 4, 12, and 26 were measured using [sup.1]H Nuclear Magnetic Resonance. Results: Trial failures (n = 7) had significantly higher LMR compared with responders (n = 19) at week 26 (0.027 [0.017‐0.33]) vs. 0.012 [0‐0.064], P = 0.013), indicating increased intestinal permeability. Multivariate analysis revealed a significant model for responders (n = 19) versus failures (n = 12) at all time points based on their fecal (P < 0.0001) and plasma (P = 0.005) metabolomic profiles, whereas urine metabolomic profiles did not differ between groups (P = 1). Fecal N‐acetyl glycoprotein GlycA correlated with Health Assessment Questionnaire Disability Index (coefficient = 0.50; P = 0.03) and fecal propionate correlated with American College of Rheumatology 20 response at week 26 (coefficient = 27, P = 0.02). Conclusion: Intestinal permeability and fecal and plasma metabolomic profiles of patients with PsA were associated with the primary clinical trial end point, failure versus responder.
INTRODUCTION Encouraged by the field of pharmacomicrobiomics, proposing how gut permeability (1,2) and microbial enzymatic products may affect the bioavailability, clinical efficacy, and toxicity of disease‐modifying antirheumatic drugs (DMARDs), the [...]
INTRODUCTION Encouraged by the field of pharmacomicrobiomics, proposing how gut permeability (1,2) and microbial enzymatic products may affect the bioavailability, clinical efficacy, and toxicity of disease‐modifying antirheumatic drugs (DMARDs), the [...]